Pacira BioSciences, Inc. (PCRX) CEO Dave Stack on Q3 2021 Results - Earnings Call TranscriptSeeking Alpha • 11/03/21
FLEXION THERAPEUTICS INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Flexion Therapeutics, Inc. - FLXNPRNewsWire • 11/02/21
Pacira Receives Notice of Allowance for New Patent Covering EXPAREL CompositionGlobeNewsWire • 11/02/21
SHAREHOLDER ALERT: Monteverde & Associates PC Announces an Investigation of Flexion Therapeutics, Inc. - FLXNPRNewsWire • 10/30/21
Earnings Preview: Flexion Therapeutics (FLXN) Q3 Earnings Expected to DeclineZacks Investment Research • 10/27/21
Pacira to Report Third Quarter 2021 Financial Results on Wednesday November 3, 2021GlobeNewsWire • 10/27/21
ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of Flexion Therapeutics, Inc.PRNewsWire • 10/11/21
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation into the Fairness of the Merger of Flexion Therapeutics, Inc. with Pacira BioSciences, Inc.Newsfile Corp • 10/11/21
Shareholder Alert: Ademi LLP investigates whether Flexion Therapeutics, Inc. has obtained a Fair Price in its transaction with PaciraPRNewsWire • 10/11/21
Flexion Merger Investigation: Halper Sadeh LLP Announces Investigation Into Whether the Sale of Flexion Therapeutics, Inc. Is Fair to Shareholders; Investors Are Encouraged to Contact the Firm – FLXNBusiness Wire • 10/11/21
Flexion Therapeutics shares soar 39% premarket on news to be acquired by Pacira BiosciencesMarket Watch • 10/11/21
Pacira BioSciences to Acquire Flexion Therapeutics Further Expanding Leadership Position in Non-Opioid Pain ManagementGlobeNewsWire • 10/11/21
Pacira BioSciences Notified of Abbreviated New Drug Application Filing for EXPAREL®GlobeNewsWire • 10/04/21
Flexion Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewsWire • 10/01/21